AOD-9604: EMA vs FDA Regulatory Approach

What Is AOD-9604?

AOD-9604 is a synthetic peptide corresponding to amino acids 176 through 191 of the C-terminal region of human growth hormone, with an added tyrosine residue at the N-terminus. Researchers at Monash University in Melbourne first isolated this fragment to study whether the fat-metabolizing properties of growth hormone could be separated from its diabetogenic and growth-promoting effects 1.

The peptide was developed commercially by Metabolic Pharmaceuticals Ltd., an Australian biotech company that advanced it through early-phase clinical trials for obesity during the early 2000s.

Mechanism of Action

AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without activating the growth hormone receptor's full signaling cascade. In obese mice, chronic treatment with the fragment reduced body weight gain and did not alter IGF-1 levels or impair insulin sensitivity 1. This selectivity made it an attractive candidate for a weight-loss drug that would avoid the glucose dysregulation associated with full-length growth hormone therapy.

Development History

Metabolic Pharmaceuticals conducted Phase I and Phase II trials in Australia between 2001 and 2007. The Phase IIb trial enrolled approximately 300 obese participants and tested multiple oral doses over 12 weeks. Results showed a modest reduction in body weight compared to placebo, but the effect size did not meet the company's commercial threshold. Metabolic Pharmaceuticals discontinued development of the oral formulation and eventually ceased operations. No Phase III trial was ever initiated 2.

FDA Regulatory Status of AOD-9604

The FDA has never approved AOD-9604 as a finished drug product for any indication. No New Drug Application (NDA) or Biologics License Application (BLA) has been submitted for the peptide. A search of the Drugs@FDA database returns no results for AOD-9604 or HGH fragment 176-191 3.

503A Compounding Pathway

Despite the absence of finished-product approval, AOD-9604 is available in the United States through section 503A of the Federal Food, Drug, and Cosmetic Act. Under this provision, licensed pharmacists can compound medications using bulk drug substances for individual patients who hold valid prescriptions 4.

The FDA maintains a list of bulk drug substances that may be used in 503A compounding. AOD-9604 was nominated for inclusion on this list and evaluated by the FDA's Pharmacy Compounding Advisory Committee (PCAC). The committee reviewed available safety and chemistry data before providing its recommendation to the agency 2.

What "Not FDA-Approved" Means in Practice

A compounded AOD-9604 product carries no FDA-approved labeling, no standardized package insert, and no required post-marketing surveillance program. The FDA does not verify the efficacy of compounded drugs before they reach patients. Quality control depends entirely on the compounding pharmacy's adherence to United States Pharmacopeia (USP) standards and state board of pharmacy regulations 4.

FDA Adverse Event Reporting

The FDA's Adverse Event Reporting System (FAERS) is the primary post-market safety surveillance tool for drugs in the US. Because AOD-9604 is not a commercially marketed approved product, adverse event reporting is voluntary and inconsistent. Clinicians and patients can submit reports through MedWatch, but the FDA has not published any safety signals specific to AOD-9604 as of May 2026 5.

EMA Position on AOD-9604

The European Medicines Agency has never received a marketing authorization application for AOD-9604. No European Public Assessment Report (EPAR) exists for this peptide. The EMA's public database of authorized medicines contains no entry for AOD-9604 under any trade name or International Nonproprietary Name (INN).

Why No Application Was Filed

Metabolic Pharmaceuticals, the original developer, was an Australian company that focused its regulatory strategy on the Australian Therapeutic Goods Administration (TGA) and, to a lesser extent, the FDA pathway. The Phase IIb results were not strong enough to justify the cost of a European marketing authorization application, which requires a full dossier under the centralized or decentralized procedure 6.

European Compounding Rules Differ Sharply

Unlike the United States, the European Union does not have a unified federal compounding framework comparable to 503A. Compounding (known as "magistral preparation" in EU pharmaceutical law) is regulated at the member-state level under Article 3 of Directive 2001/83/EC. Most EU countries restrict magistral preparations to substances listed in national or European pharmacopeias. AOD-9604 does not appear in the European Pharmacopoeia, which means compounding pharmacies in most EU member states cannot legally prepare it 7.

This creates a binary outcome. In the US, a physician can prescribe AOD-9604 and a 503A pharmacy can compound it. In the EU, the same peptide is functionally unavailable through any legal channel in most countries.

Key Differences Between FDA and EMA Approaches

The regulatory divergence on AOD-9604 reflects broader philosophical differences between the two agencies regarding unapproved substances, compounding access, and patient autonomy.

Compounding Access: Open vs. Closed

The FDA's 503A pathway allows physicians to prescribe, and pharmacies to compound, bulk drug substances that have not been approved as finished products. The framework assumes that a licensed physician's clinical judgment, combined with pharmacy-level quality controls, provides sufficient patient protection for individually compounded preparations 4.

The EMA and EU member states take a more restrictive position. Magistral preparations are typically limited to substances with established pharmacopeial monographs or those with a long history of medicinal use. Novel peptides like AOD-9604 fall outside this framework entirely.

Oversight Intensity

| Dimension | US (FDA) | EU (EMA / Member States) | |---|---|---| | Product approval | None | None | | Compounding access | Available via 503A | Not available in most member states | | Quality standards | USP chapters 795/797 | National pharmacopeia standards | | Adverse event tracking | Voluntary FAERS reporting | No EudraVigilance entries | | Prescriber requirements | Valid patient-specific Rx | Not applicable (no legal supply) | | Labeling | No standardized label | No label exists |

Risk-Benefit Framing

The FDA's approach implicitly accepts a higher degree of uncertainty about efficacy in exchange for preserving physician-patient access to compounded therapies. The European model prioritizes pre-market evidence and restricts access to substances that have not passed through a formal authorization process. Neither approach is inherently superior. They reflect different regulatory cultures around medical autonomy and precautionary principles.

Clinical Evidence Informing Regulatory Decisions

The limited clinical data on AOD-9604 is a central factor in both agencies' positions. No large-scale, adequately powered, placebo-controlled Phase III trial has ever been completed.

Preclinical Findings

Heffernan et al. (2001) demonstrated that chronic administration of AOD-9604 in obese mice reduced body fat accumulation without altering circulating IGF-1 concentrations or worsening insulin resistance. The study used both wild-type and beta-3 adrenergic receptor knockout mice, showing that the lipolytic effect operated partly through beta-3 pathways 1.

Additional preclinical work from the same Monash University research group characterized the peptide's pharmacokinetics and confirmed that it did not stimulate longitudinal bone growth or produce the anti-insulin effects of full-length GH 8.

Human Trial Data

The Phase IIb trial conducted by Metabolic Pharmaceuticals tested oral AOD-9604 at doses of 1 mg, 5 mg, 10 mg, and 20 mg daily versus placebo in approximately 300 obese adults over 12 weeks. The trial reported a statistically significant but clinically modest reduction in body weight at the two highest doses.

For context, the GLP-1 receptor agonist semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% with placebo 9. The AOD-9604 effect size was substantially smaller, measured over a shorter timeframe, and assessed with an oral formulation that posed bioavailability challenges for a peptide drug.

Why the Evidence Gap Persists

Once Metabolic Pharmaceuticals ceased operations, no pharmaceutical company assumed sponsorship of further trials. The peptide entered the compounding market without additional clinical development. The Endocrine Society has not included AOD-9604 in any clinical practice guideline 10.

Safety Profile and Post-Market Surveillance

Known Adverse Effects from Trials

The Phase I and Phase II trials reported that AOD-9604 was generally well tolerated at the doses tested. Common adverse effects included mild injection-site reactions (in subcutaneous studies) and gastrointestinal symptoms (in oral studies). No serious adverse events were attributed to the peptide in published trial summaries.

The preclinical safety profile was notable for the absence of the hyperglycemic effects associated with exogenous growth hormone. AOD-9604 did not raise fasting glucose or worsen oral glucose tolerance in animal models 1.

Critical Data Gaps

The total number of human subjects exposed to AOD-9604 in controlled trials is approximately 500 across all phases. That sample size is too small to detect adverse events occurring at rates below 1 in 100. By comparison, the FDA typically requires safety databases of 1,500 or more subjects before approving a new drug for a chronic condition 11.

Long-term safety data beyond 12 weeks of exposure does not exist in the published literature. The peptide's effects on thyroid function, reproductive hormones, and cardiovascular markers over months or years of use remain unknown. Patients using compounded AOD-9604 are, in a practical sense, generating the long-term safety data that formal trials never collected.

Monitoring Recommendations

The Endocrine Society recommends baseline and periodic monitoring of IGF-1, fasting glucose, and HbA1c in patients receiving growth hormone-related therapies 12. While AOD-9604 is not full-length GH, applying this monitoring framework provides a reasonable safety net. Clinicians prescribing compounded AOD-9604 should also track lipid panels and liver enzymes given the peptide's intended metabolic effects.

What US and European Patients Should Know

Accessing AOD-9604 in the United States

US patients can obtain AOD-9604 through a licensed 503A compounding pharmacy with a valid prescription from a physician. The prescribing clinician assumes responsibility for clinical oversight, including dose selection, monitoring, and adverse event management. Patients should verify that their compounding pharmacy follows USP chapters 795 and 797 for quality assurance and ask for a Certificate of Analysis (COA) confirming peptide identity and purity 4.

Accessing AOD-9604 in Europe

Legal access to AOD-9604 in EU member states is effectively nonexistent through regulated channels. The peptide is not authorized, not listed in the European Pharmacopoeia, and not eligible for magistral compounding in most jurisdictions. Patients who obtain it through unregulated online sources face unknown risks regarding product identity, purity, sterility, and dose accuracy 7.

The Regulatory Bottom Line

Neither the FDA nor the EMA considers AOD-9604 a proven therapy. The difference is access: the US compounding framework provides a regulated (if limited) pathway, while the EU framework provides none. Patients considering AOD-9604 should discuss the evidence gaps with their clinician and establish a monitoring plan that includes metabolic panels at baseline, 6 weeks, and every 12 weeks thereafter 12.